Display options
Cite
Iannella L, Colamonici C, Curcio D, et al. 5α-reductase inhibitors: Evaluation of their potential confounding effect on GC-C-IRMS doping analysis. Drug Test Anal. 2021;doi: 10.1002/dta.3134.
Iannella, L., Colamonici, C., Curcio, D., Botrè, F., & de la Torre, X. (2021). 5α-reductase inhibitors: Evaluation of their potential confounding effect on GC-C-IRMS doping analysis. Drug testing and analysis, . https://doi.org/10.1002/dta.3134
Iannella, Loredana, et al. "5α-reductase inhibitors: Evaluation of their potential confounding effect on GC-C-IRMS doping analysis." Drug testing and analysis vol. (2021). doi: https://doi.org/10.1002/dta.3134
Iannella L, Colamonici C, Curcio D, Botrè F, de la Torre X. 5α-reductase inhibitors: Evaluation of their potential confounding effect on GC-C-IRMS doping analysis. Drug Test Anal. 2021 Jul 27; doi: 10.1002/dta.3134. Epub 2021 Jul 27. PMID: 34318592.
Copy Download .nbib Format: NLM
Share it on

Drug Test Anal. 2021 Jul 27; doi: 10.1002/dta.3134. Epub 2021 Jul 27.

5α-reductase inhibitors: Evaluation of their potential confounding effect on GC-C-IRMS doping analysis.

Drug testing and analysis

Loredana Iannella, Cristiana Colamonici, Davide Curcio, Francesco Botrè, Xavier de la Torre

Affiliations

  1. Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Rome, Italy.
  2. ISSUL - Institute des sciences du sport, Université de Lausanne, Lausanne, Switzerland.

PMID: 34318592 DOI: 10.1002/dta.3134

Abstract

5α-reductase inhibitors (5-ARIs) are considered by the World Anti-doping Agency as potential confounding factors in evaluating the athlete steroid profile, since they may interfere with the urinary excretion of several diagnostic compounds. We herein investigated 5α-reductase inhibitors from a different perspective, by verifying their influence on the carbon isotopic composition of 5α- and 5β-reduced testosterone and nandrolone metabolites. The GC-C-IRMS analysis was performed on a set of urine samples collected from three male Caucasian volunteers after the acute and chronic administration of finasteride in combination with the intake of 19-norandrostenedione, a nandrolone precursor. The excretion and the isotopic profile of androsterone (A), etiocholanolone (Etio) 5α-androstane-3α,17β-diol (5αAdiol), and 5β-androstane-3α,17β-diol (5βAdiol) were determined as well as those of 19-norandrosterone (19-NA) and 19-noretiocholanolone (19-NE). Pregnanediol (PD) and pregnanetriol (PT) were also measured as endogenous reference compounds to define the individual endogenous isotopic profile. Our results confirmed the impact of finasteride, especially if chronically administered, on the enzymatic pathway of testosterone and nandrolone, and pointed out the influence of 5-ARIs on δ

© 2021 John Wiley & Sons, Ltd.

Keywords: 19-norsteroids; 5α-reductase inhibitors; doping control; isotope ratio mass spectrometry; masking agents

References

  1. Clark AF. Steroid Δ4-reductases: their physiological role and significance. In: Hobkirk R, ed. Steroid Biochemistry: Volume I. CRC Press; 2017. - PubMed
  2. Langlois VS, Zhang D, Cooke GM, Trudeau VL. Evolution of steroid-5α-reductases and comparison of their function with 5β-reductase. Gen Comp Endocrinol. 2010;166(3):489-497. - PubMed
  3. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell OD, Russell DW. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest. 1993;92(2):903-910. - PubMed
  4. Russell DW, Wilson JD. Steroid 5a-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63(1):25-61. - PubMed
  5. Stiles AR, Russell DW. SRD5A3: a surprising role in glycosylation. Cell. 2010;142(2):196-198. - PubMed
  6. Moon YA, Horton JD. Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J Biol Chem. 2003;278(9):7335-7343. - PubMed
  7. Marchetti PM, Barth JH. Clinical biochemistry of dihydrotestosterone. Ann Clin Biochem. 2013;50(2):95-107. - PubMed
  8. Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(4):2-7. - PubMed
  9. Essah PA, Wickham EP, Nunley JR, Nestler JE. Dermatology of androgen-related disorders. Clin Dermatol. 2006;24(4):289-298. - PubMed
  10. Gerst C, Dalko M, Pichaud P, Galey JB, Buan B, Bernard BA. Type-1 steroid 5α-reductase is functionally active in the hair follicle as evidenced by new selective inhibitors of either type-1 or type-2 human steroid 5α-reductase. Exp Dermatol. 2002;11(1):52-58. - PubMed
  11. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434-441. - PubMed
  12. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17-25. - PubMed
  13. Rittmaster RS. 5Α-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab. 2008;22(2):389-402. - PubMed
  14. Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M. The role of 5-alpha reductase inhibitors in prostate pathophysiology: is there an additional advantage to inhibition of type 1 isoenzyme? J Can Urol Assoc. 2009;3:109-114. - PubMed
  15. Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012;9(11):2927-2932. - PubMed
  16. Irwig MS. Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2015;22(3):248-253. - PubMed
  17. Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56-62. - PubMed
  18. Melcangi RC, Santi D, Spezzano Ret al. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. J Steroid Biochem Mol Biol 2017;171:229-235. - PubMed
  19. Chau CH, Figg WD. Revisiting 5α-reductase inhibitors and the risk of prostate cancer. Nat Rev Urol. 2018;15(7):400-401. - PubMed
  20. Aggarwal S, Thareja S, Verma A, Tilak Raj B, Kumar M. An overview on 5α-reductase inhibitors. Steroids. 2010;75(2):109-153. - PubMed
  21. Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012;2012(53012):1-18. - PubMed
  22. WADA Technical Document - TD2021EAAS. Measurement and Reporting of Endogenous Anabolic Androgenic Steroid (EAAS) Markers of the Urinary Steroid Profile. https://www.wada-ama.org/sites/default/files/resources/files/td2021eaas_final_eng.pdf. Published 2021. Accessed April 15, 2021. - PubMed
  23. Geyer H, Nolteernsting E, Schänzer W. Finasteride-a substance for manipulation in dope control. In: Recent Advances in Doping Analysis, Proceedings of the 17th Cologne Workshop on Dope Analysis. Sport und Buch Strauβ; 1999:71-80. - PubMed
  24. Mareck U, Geyer H, Opfermann G, Thevis M, Schänzer W. Factors influencing the steroid profile in doping control analysis. J Mass Spectrom. 2008;43(7):877-891. - PubMed
  25. Kuuranne T, Saugy M, Baume N. Confounding factors and genetic polymorphism in the evaluation of individual steroid profiling. Br J Sports Med. 2014;48(10):848-855. - PubMed
  26. Marques M, Bizarri C, Cardoso J, de Aquino Neto F. Effect of finasteride on the urinary steroid profile: a case study. In: Recent Advances in Doping Analysis, Proceedings of the 17th Cologne Workshop on Dope Analysis. Sport und Buch Strauβ; 1999:317-322. - PubMed
  27. Simões S, Vitoriano B, Manzoni C, de la Torre X. 5-Alpha reductase inhibitors detection in doping analysis. In: Recent Advances in Doping Analysis, Proceedings of the 23rd Cologne Workshop on Dope Analysis. Sport und Buch Strauβ; 2005:199-209. - PubMed
  28. Thevis M, Geyer H, Mareck U, Flenker U, Schänzer W. Doping-control analysis of the 5α-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite. Ther Drug Monit. 2007;29(2):236-247. - PubMed
  29. Iannella L, Colamonici C, Curcio D, Botrè F, de la Torre X. Improving the confirmation of 19-norsteroids abuse in doping controls: a new gas chromatography coupled to isotope ratio mass spectrometry method for the analysis of 19-norandrosterone and 19-noretiocholanolone. Drug Test Anal. 2020;13(4):1-15. https://doi.org/10.1002/dta.2985 - PubMed
  30. WADA Technical Document - TD2021NA. Harmonization of analysis and reporting of 19-norsteroids related to nandrolone. https://www.wada-ama.org/sites/default/files/resources/files/td2021na_final_eng.pdf. Published 2021. Accessed January 25, 2021. - PubMed
  31. WADA Technical Document - TD2021IRMS. Detection of synthetic forms of prohibited substances by GC/C/IRMS. https://www.wada-ama.org/sites/default/files/resources/files/td2021irms_final_eng.pdf. Published 2021. Accessed April 15, 2021. - PubMed
  32. de la Torre X, Colamonici C, Curcio D, Molaioni F, Pizzardi M, Botrè F. A simplified procedure for GC/C/IRMS analysis of underivatized 19-norandrosterone in urine following HPLC purification. Steroids. 2011;76(5):471-477. - PubMed
  33. de la Torre X, Colamonici C, Curcio D, Molaioni F, Botrè F. A comprehensive procedure based on gas chromatography-isotope ratio mass spectrometry following high performance liquid chromatography purification for the analysis of underivatized testosterone and its analogues in human urine. Anal Chim Acta. 2012;756:23-29. - PubMed
  34. Mazzarino M, Braganò MC, Donati F, de la Torre X, Botrè F. Effects of propyphenazone and other non-steroidal anti-inflammatory agents on the synthetic and endogenous androgenic anabolic steroids urinary excretion and/or instrumental detection. Anal Chim Acta. 2010;657(1):60-68. - PubMed
  35. Mazzarino M, Braganò MC, de la Torre X, Molaioni F, Botrè F. Relevance of the selective oestrogen receptor modulators tamoxifen, toremifene and clomiphene in doping field: endogenous steroids urinary profile after multiple oral doses. Steroids. 2011;76(12):1400-1406. - PubMed
  36. Mazzarino M, Abate MG, Alocci R, et al. Urine stability and steroid profile: towards a screening index of urine sample degradation for anti-doping purpose. Anal Chim Acta. 2011;683(2):221-226. - PubMed
  37. Zhang Y, Tobias HJ, Brenna JT. Steroid isotopic standards for gas chromatography-combustion isotope ratio mass spectrometry (GC-C-IRMS). Steroids. 2009;74(3):369-378. - PubMed
  38. Declaration of Helsinki (1964). Br Med J. 1996;313:1448-1449. - PubMed
  39. de la Torre X, Colamonici C, Iannone M, Jardines D, Molaioni F, Botrè F. Detection of clostebol in sports: accidental doping? Drug Test Anal. 2020;12(11-12):1561-1569. - PubMed
  40. Hullstein I, Sagredo C, Hemmersbach P. Carbon isotope ratios of nandrolone, boldenone, and testosterone preparations seized in Norway compared to those of endogenously produced steroids in a Nordic reference population. Drug Test Anal. 2014;6(11-12):1163-1169. - PubMed

Publication Types